Journal
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
Volume 51, Issue 5, Pages -Publisher
WILEY
DOI: 10.1111/eci.13472
Keywords
all‐ cause mortality; cardiovascular disease; L‐ homoarginine; nitric oxide; South Africa
Funding
- SANPAD (South Africa-Netherlands Research Programme on Alternatives in Development)
- PHRI (Population Health Research Institute)
- MRC (Medical Research Council) of South Africa
- South African NRF (National Research Foundation) [2069139, FA2006040700010]
- North-West University
- Roche Diagnostics
- German Academic Exchange Service (DAAD)-NRF
Ask authors/readers for more resources
The study found that higher levels of L-homoarginine in a black South African population are associated with reduced risk of 10-year cardiovascular and all-cause mortality. Further investigation into regulating L-homoarginine levels as a therapeutic target in managing cardiovascular disease is recommended.
Background Increasing evidence suggests that L-homoarginine, an endogenous analogue of the amino acid L-arginine, may have beneficial effects on vascular homeostasis. We examined whether L-homoarginine is associated with 10-year risk of all-cause and cardiovascular mortality in a black South African population. Methods We included 669 black South African participants (mean age 59.5 years), 143 of whom died during the 10-year follow-up period. Mortality data were acquired via verbal autopsy. Plasma L-homoarginine (and other related markers) were analysed with liquid chromatography-tandem mass spectrometry. Results Survivors had higher L-homoarginine levels compared with nonsurvivors (1.25 mu M vs. 0.89 mu M; P < .001). Multivariable Cox regression analyses revealed that higher plasma L-homoarginine predicted a reduction in 10-year cardiovascular (hazard ratio [HR] per SD increment, 0.61; 95% CI 0.50 to 0.75) and all-cause (hazard ratio [HR] per SD increment, 0.59; 95% CI 0.41 to 0.84) mortality risk. Conclusion Higher L-homoarginine levels are associated with reduced risk of 10-year cardiovascular and all-cause mortality. Regulation of L-homoarginine levels as a therapeutic target in the management of cardiovascular disease should be investigated.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available